BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
231 hedge funds and large institutions have $1.7B invested in bluebird bio in 2021 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 81 increasing their positions, 60 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.07% more ownership
Funds ownership: 6.03% → 6.11% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less call options, than puts
Call options by funds: $26.1M | Put options by funds: $32.6M
Holders
231
Holding in Top 10
1
Calls
$26.1M
Puts
$32.6M
Top Buyers
| 1 | +$61.5M | |
| 2 | +$25.4M | |
| 3 | +$24.2M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18M |
| 5 |
JPMorgan Chase & Co
New York
|
+$17.1M |
Top Sellers
| 1 | -$102M | |
| 2 | -$30.1M | |
| 3 | -$29.5M | |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$17.6M |
| 5 |
Two Sigma Investments
New York
|
-$6.9M |